Children With HIV May Benefit From Alendronate
Alendronate treatment is well-tolerated and improved bone mineral density (BMD) with no safety concerns in children and adolescents with perinatally acquired HIV.
Alendronate treatment is well-tolerated and improved bone mineral density (BMD) with no safety concerns in children and adolescents with perinatally acquired HIV.
Safety and efficacy of isoniazid for the prevention of tuberculosis may vary between HIV-infected pregnant and postpartum women.
According to the United States Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, preliminary data from 2017 show that gay, bisexual, and other men who have sex with men accounted for 67% of incident diagnoses of HIV.
Of the estimated 38,739 new cases of HIV reported in 2017, 70% were among men who have sex with men. Use of daily PrEP can virtually eliminate the risk of developing HIV, if used as prescribed.
In women with HIV, lower education and hepatitis C co-infection are independently associated with the onset of menopause before age 45 years.
Distribution of HIV self-tests among men who have sex with men can increase testing and newly identified infections.
The test may help clinicians tailor HIV therapy for their patients.
Age, racial/ethnic, and risk category disparities exist among patients who discontinue preexposure prophylaxis treatment after initiation.
A recent study supports the efficacy of interprofessional collaboration in linking patients with HIV to care services.
Researchers sought to assess the acceptance of opt-out HIV screening in outpatient settings in the United States.